TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Device-oriented cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal Body Temperature 90 Minutes After Randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline Fetal Heart Rate (FHR) After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Change in Peabody Picture Vocabulary Test-Revised score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Episode Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of subjects engaged in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects prescribed antiretroviral therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects that have achieved viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SF12 Physical Component Score Between Pre-operation and 12 Months Post-operation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Change in Bipolar Illness Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Necessary Medication Adjustments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Variations in cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of Magseed placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage vital respiratory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Radiographic Union at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic Union at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Echocardiographic measurements of VOP and Sao i
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vocal cord function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With EHR Documentation of Goals of Care Discussions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Memorial Symptom Assessment Scale Psychological Sub Dimension
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parsitaemia detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total tumor survival time
Endpoint domain: Mortality/survival
Primary endpoint: Audit & Feedback Feasibility
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Audit & Feedback Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Audit & Feedback Appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Discharge from ICU
Endpoint domain: Mortality/survival
Primary endpoint: Concordance with MSIS criteria for defining infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of children with protective VZV Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PTSD symptoms and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Markers in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in dietary pattern
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Changes in sleep pattern
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in mental well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in maximum oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of endogenous AAS metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of blood or lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reproducibility of the planned pre-operative centre of rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adherence (Including Withdrawals)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum observed concentration (Cmax) of JNJ-42721458
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum plasma concentration (tmax) of JNJ-42721458
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PVB19 and HHV6 virus genome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood flow pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of the combination of SU011248 and paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: number of new renal failure patients with failed arteriovenous fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative Jaw Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity measured by 18F-X microglial binding site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax - Maximum Plasma Concentration of BIA 9-1067
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopment Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients with debris captured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of stress fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in total score of the Hamilton Depression Rating Scale (HAM-D17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disability-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in total testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acute hypercapnic respiratory failure episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Consumption of Xalatan/Xalacom bottles per year per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical Benefit (CB) defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) ≥12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on physician's clinical treatment decision making
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal bone loss around implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in endogenous blood levels of FSH and LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in endogenous blood levels of steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of Alectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/tolerability of ZN-A-1041 as a monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Safety/tolerability of ZN-A-1041 in combination with Capecitabine and Trastuzumab
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of ZN-A-1041 in combination with Capecitabine and Trastuzumab
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) by Relationship to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in size of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in number of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects with polycystic ovary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of subjects with hirsutism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absence of Revision
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients included in a province-wide registry of NGS panel-based testing results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in use of NGS panel-based testing in Ontario clinical genetic testing laboratories
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clearing of pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pharmacokinetics of CKD-501 1mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of months without surgical hernia recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in Severity of Insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants Who Are CW-Compliant and CW-Noncompliant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical Pulmonary Infection Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Determination of Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of Recommended Phase 2 Dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioral performance (Accuracy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral performance (Reaction times)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance-Corrected Near Visual Acuity (DCNVA) at 40 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Intravitreal Aflibercept Injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence of prostate intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in peak nasal inspiratory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Liver Cu Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With an Acceptable Level of Severe Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With an Acceptable Level of Treatment Related Urinary and Rectal Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: percent of patients who show complete or partial remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of device-related and procedure-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death within 1 year of operation
Endpoint domain: Mortality/survival
Primary endpoint: Serum concentrations of Neostigmine and Glycopyrrolate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Schizophrenia symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cases with genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain functional interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Opioid craving
Endpoint domain: Adverse events/effects
Primary endpoint: mortality based on COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Function of suprascapular nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Parent BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in arterial oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of lesion at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cases of HF stage C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum Trough Concentrations (Ctrough) of Daratumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Composite endpoint of stroke, systemic embolism, life-threatening or major bleeding and all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Pain after colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in step counts per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in minutes of moderate-to-vigorous physical activity (MVPA) per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma lipid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sleep Measures
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Infant State
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Metabolic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of RNAIII expression and sprD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in scores on Facial Expression Identification Task (FEIT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Microbiological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Completion (Number of Families Who Completed Treatment)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IDEA Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Differences in GIGD (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved function and capacity of the neorectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ototoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognition in Affective Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of integrity of nasal septum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of HIV-exposed infants presenting for DNA PCR testing by 2 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of HIV-positive mothers retained in PMTCT care at 6 months post-delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Time to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Polycythemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Indirect hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Body Water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with neurologic and/or psychiatric adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Phenotype and function of peripheral blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of immune-related adverse events (irAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Optimal size of OPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of 14C-JNJ-39823277
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of 14C-JNJ-39823277
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-Life Period (T1/2) of 14C-JNJ-39823277
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative hemorrhage of the surgical eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change on Becks Depression Inventory-II (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects That Reach Castration by Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Healing of the anal fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adipose tissue lipolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to First Occurrence of 3-point Major Adverse Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: Febrile Neutropenia (FN) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: All cause mortality until 3 years of age
Endpoint domain: Mortality/survival
Primary endpoint: Recession depth (Change in the amount of root coverage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: number of HF hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Visibility during colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time used to reach the cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with moderate to severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of mediastinal staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in primary diagnosis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in comorbid diagnosis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H&E Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma copeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of epidural analgesia-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Relative Vertical Clinical Attachment Level (RVCAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence of Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity measured by Huskisson's VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-free survival after first randomization
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free survival after second and third randomization
Endpoint domain: Mortality/survival
Primary endpoint: Time to Reach the Maximum Observed Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes